Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemtuzumab ozogamicin
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a humanized IgG4 kappa monoclonal antibody (gemtuzumab) covalently linked to the cytotoxic agent calicheamicin. The antibody specifically targets the myeloid cell surface antigen CD33, which is expressed on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). Upon binding to CD33-positive cells, the complex is internalized and calicheamicin is released inside the cell, where it induces double-stranded DNA breaks leading to cell cycle arrest and apoptosis. Gemtuzumab ozogamicin is primarily indicated for the treatment of newly diagnosed or relapsed/refractory CD33-positive AML in adults and children[1][2][3][4][5][6][8].
- Brand names
- Mylotarg
- Other names
- gemtuzumab ozogamicinCMA-676CMA676CMA 676
02
Targets
DNACD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on gemtuzumab ozogamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemtuzumab ozogamicin.